Kailera Therapeutics to Present at ObesityWeek 2026

November 10, 2026

- *Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum*
- *Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity*

WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity.

“People living with obesity have diverse and often highly individualized treatment needs, underscoring the importance of developing new therapeutic options,” said Scott Wasserman, M.D., Chief Medical Officer of Kailera Therapeutics. “The research we are presenting at ObesityWeek reflects both the rigor of our clinical development program and our focus on better understanding the real-world obesity landscape and how our differentiated GLP-1-based pipeline can address unmet patient needs.”

ObesityWeek 2026 Presentations

Title	Presenter	Date
Rationale and design of the KaiNETIC-1 and -2 trials of ribupatide in people living with obesity	Dr. Vanita Aroda	November 15
Rationale and design of the KaiNETIC-3 trial of ribupatide in people with obesity and no diabetes	Dr. Ildiko Lingvay	November 15
Natural history and real-world effectiveness of obesity management medications: REFLECT design/methods	Briain O Hartaigh, Kailera	November 16
Quantifying the Clinical Unmet Need in Adults with Class II and III Obesity in the United States	Molly Plotkin, Kailera	November 16

In addition, Hengrui Pharma will present findings from its Phase 3 HARBOR clinical program evaluating safiglipron (KAI-7535, HRS-7535), an investigational oral small-molecule GLP-1 receptor agonist. Safiglipron is being developed by Kailera Therapeutics outside Greater China.

Additional Presentations by Hengrui Pharma at ObesityWeek 2026

Title	Date
HRS-7535 for Weight Management in Chinese Adults with Overweight or Obesity: Phase 3 HARBOR-1 Study	November 15
HRS-7535 Effect on Glycaemic Status in Prediabetes: HARBOR-1 Subgroup Analysis	November 15

All presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the ObesityWeek website.

About Ribupatide
Ribupatide is a GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight.

Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program.

Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and

Kailera plans to initiate global Phase 3 trials in obesity in the first half of 2027.

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of safiglipron (also known as KAI-7535), a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera's vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera's portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "suggest," "plan," "goal," "vision," "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption "Risk Factors" in Kailera's filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Contact Information

Maura Gavaghan
Vice President, Investor Relations
maura.gavaghan@kailera.com

Anna Robinson
Vice President, Communications
anna.robinson@kailera.com